Exposure to Environmental Pollution, Non-occupationalTROPICOZNCT01981135
Interaction Effects of Temperature and Ozone
A study testing Clean Air and Ozone in people with Exposure to Environmental Pollution, Non-occupational, run by Environmental Protection Agency (EPA) at 1 site in United States.
Trial summary
Purpose: The purpose of this protocol is to understand how individuals respond to the air pollutant ozone at elevated temperatures. Ultimately, this will help us understand what the risks from poor air quality are during a heat wave. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Exposure to Environmental Pollution, Non-occupational
- What is being tested?
- Clean Air and Ozone
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2011to Jan 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 1. Pass a physical exam performed by study physicians during the screening visit under a separate protocol.
- 2. Normal lung function:
- FVC > 75 % of that predicted for gender, ethnicity, age and height.
- FEV1 > 75 % of that predicted for gender, ethnicity, age and height.
- FEV1/FVC ratio > 75 % of predicted values. 3. Oxygen saturation of > 96 %. 4. Ability to tolerate intervals of moderate exercise.
Who cannot join
- 1. A history of chronic illnesses such as diabetes, rheumatological diseases, immunodeficiency state, known clinically significant cardiac disease (including myocardial infarction, congestive heart failure and angina), chronic respiratory diseases such as chronic obstructive pulmonary disease, asthma and lung cancer.
- 2. If the subject is pregnant, attempting to become pregnant or breastfeeding. 3. Subjects currently taking medications which may impact the results of the ozone challenge or interfere with any other medications potentially used in the study (to include systemic steroids and beta blockers). Subjects must refrain from all over the counter anti-inflammatory agents, and anti-oxidants for a period of one week prior to exposure. Medications not specifically mentioned here may be reviewed by the investigators prior to a subject's inclusion in the study.
- 4. Smoking history within 2 years of the study. 5. Untreated hypertension (≥ 150 systolic, ≥ 90 diastolic). 6. Skin diseases or sensitivity precluding the use of ECG electrodes. 7. Symptom score greater than 21 (out of a possible 40-see accompanying score sheet) for total symptom score. Only one score may be equal to 3.
- 8. Dementia. 9. Unspecified illness or condition which in the judgment of the investigator might increase the risk associated with inhalation challenge or exercise.
- 10. Subjects who do not understand or speak English. 11. Subjects who are unable to perform moderate exercise.
Trial locations and contacts
1 site in 1 country.
United States1 site
U.S. EPA Human Studies Facility
Chapel Hill, North Carolina, 27514
About this study
Purpose: The purpose of this protocol is to understand how individuals respond to the air pollutant ozone at elevated temperatures. Ultimately, this will help us understand what the risks from poor air quality are during a heat wave.
Participants: We will recruit up to 30 healthy adults, 18-55 years old, to participate in this study.
Read more
Procedures (methods): Subjects will be exposed to clean air and to 0.3 ppm of ozone for 2 hours with intermittent exercise in a controlled environment chamber. For each exposure the temperature in the chamber will be between 31-34oC (88-93 oF). Because the aim of the study is to mimic high exposure during a heat wave, we will perform exposures only on days when mean ambient temperatures was less than 24 oC in Chapel Hill on the previous day.
Primary endpoints will include spirometry and Heart Rate Variability monitoring. Secondary endpoints will include analysis of blood clotting/coagulation factors, and analysis of soluble factors present in plasma.
Read the detailed description
Over the past decades, air quality in the U.S. has improved significantly. Even so, millions of people in the U.S. still live in counties that do not meet air quality standards for one or more pollutants. Global climate change is widely accepted to be occurring and is thought to have a range of major and potentially adverse effects on the ecosystem. Additionally, changes in the climate can lead to higher concentrations of harmful air pollutants, and the presence of some air pollutants in the atmosphere can also accelerate climate change. Health effects are impacted by complex interactions between climate change and air quality. Research is needed to identify the public health consequences of these interactions. One aspect that has been understudied is how physiological responses to elevated temperature are impacted by the additional stressor of air pollution.
Several epidemiological studies have shown a strong link between exposure to air pollution and adverse cardiopulmonary effects, such as respiratory tract infections, exacerbation of asthma, chronic bronchitis, ischemic heart disease, and stroke [1-3]. Ozone is a major component of photochemical smog. Controlled human exposure studies have been critical in demonstrating that it can cause decrements in lung function [4-10] and lung inflammation.[11-13] The inflammation includes increased neutrophils and soluble pro-inflammatory mediators in the lower airways [14, 15].
The majority of these studies involved controlled exposures to relatively high (0.1 - 0.4ppm) concentrations for short periods of time (typically 2 hours). These short-term exposure studies are useful because a) they provide the strongest and most quantifiable exposure-response data and b) they allow the investigation of biological changes that in themselves are transient and inconsequential but can be extrapolated to predict health outcomes in susceptible populations or in long-term exposures. For example, healthy individuals exposed to 0.4ppm ozone exposure for 2hr [16] showed a13.5 % decrement in FEV1, often accompanied by only mild symptoms such as tracheobronchial irritation and cough. However, by 3hours after exposure, these symptoms had largely disappeared and only a 2.7% FEV1 decrement was detectable. By 24hrs, even at higher ozone concentrations the recovery phase has normally completed. The primary public health concern is in individuals with respiratory disease. If these same changes occurred in a person with reduced reserve, the ozone-induced changes would be superimposed on preexisting pulmonary impairment and may have significant health effects.
Despite almost 30 years of research into the effects of ozone, there are very few studies of the interaction between ozone and temperature. Although ozone is normally elevated when the weather is dry and hot, most controlled chamber studies are performed at moderate temperatures (70-75 oF). Those studies that addressed higher temperatures were generally performed in the run-up to the Los Angeles Olympics in 1984 and centered on impairment of exercise performance. For example, Gibbons and Adams studied ten aerobically trained young adult females exercised continuously at 66% of maximum O2 uptake for 1 h while exposed orally to filtered air and 0.15 and 0.30 ppm ozone in both moderate (24 degrees oC) and hot (35 degrees oC) ambient conditions and showed that subjects were more likely to cease exercising prematurely at hot temperatures.[17] Gong studied elite cyclists and showed similar results.[18] Folinsbee et al., studied the effects of a 2-h exposure to high level ozone (0.5 ppm) in 14 nonsmoking males under four environmental conditions (64.4, 80.0, 85.2, and 92.0 oF) and found that the greatest decrease in FVC occurred when ozone exposures were at the highest temperature.[19]
Those cited studies have focused on respiratory outcomes. Yet it is becoming clear that ozone may have systemic and cardiac effects. Ozone reacts rapidly with respiratory tissues and is not absorbed or transported to extrapulmonary sites. However, recent studies have also shown associations between long-term ozone exposure and cardiovascular morbidity [20, 21]. In addition, short-term exposures to ozone may cause minor transient changes in high frequency heart rate variability (HRV) in healthy adults [22]. Experimental studies have shown that heat stress can have a similar modest effect on this component of HRV. [23] The effect of the combination has not been studied to date. Epidemiology studies assessing the ozone-temperature-cardiac relationship have generally been uninformative since high ozone days normally occur during hot weather. Traditional methods are not suitable to discriminate between the effects of ozone and temperature, let alone their interaction. Those that have studied the relationship have shown a negative association between temperature and ozone-mortality due to increased use in air conditioning. [24] A very recent study, however, using novel approaches examined whether ozone modified the associations between temperature and cardiovascular mortality in 95 large communities in the USA, 1987-2000, in summer. They found that a 10oC increase in temperature on the same day was associated with an increase in mortality by 1.17% and 8.31% for the lowest and highest level of ozone concentrations in all communities, respectively.[25]
The purpose of this study is to perform the first controlled chamber study in order to understand the cardiovascular changes resulting from the interaction between heat and ozone. The information obtained from this study will enable the EPA to evaluate better the risks from air pollutants during a heat wave and provide advice on activities to mitigate the effects.
- Being tested
- Clean Air, Ozone
- Keywords
- Controlled Human exposure study, Air Pollution, Temperature, Lung Function, Cardiovascular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clean AirOther
Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
OzoneOther
Also called O3
Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
| Study group | Role | What they receive |
|---|---|---|
| Clean Air | Sham comparator | Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Receives: Other: Clean Air |
| Ozone | Experimental | Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Receives: Other: Ozone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forced expired volume in the first second (FEV1)
Forced expired volume in the first second (FEV1) is determined by spirometry performed on a dry seal spirometer interfaced to a computer.
Measured: Pre exposure to 24hours post exposure
Secondary outcomes (4)
Index of clotting/coagulation factor
Index of clotting/coagulation factors are the mean % changes in a basket of clotting/coagulation factors (d-dimer, PA-1, tPA, vWillebrand factor and plasminogen) in the blood following exposure to ozone vs. clean air.
Measured: Pre exposure to 24hours post exposure
Index of inflammatory markers
Index of inflammatory markers is the mean % changes in a basket of factors related to systemic inflammation (IL-6, IL-8, TNF-a, IL-b, CRP) in the blood following exposure to ozone vs. clean air.
Measured: Pre exposure to 24hours post exposure
Forced Vital Capacity
Forced Vital Capacity(FVC) is determined by spirometry performed on a dry seal spirometer interfaced to a computer.
Measured: Pre exposure to 24hours post exposure
Changes in heart rate variability
10 minute electrocardiogram recording (measured by Holter ECG) in which the subject has been resting for 20 minutes prior. Collected on a Mortara H12+ 12-Lead ECG Recorder (Mortara Instrument, Inc., Milwaukee, WI). The digitally recorded ECGs are sampled at 180 Hz.
Measured: Pre exposure to 24hours post exposure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Nov 2013 (estimated)
- Study startSep 2011
- Primary completionMar 2014
- Study completionJan 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Exposure to Environmental Pollution, Non-occupationalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 16 participants (actual)
Sponsor and investigators
- Lead sponsor
- Environmental Protection Agency (EPA)
- Sponsor type
- US federal agency
- Responsible party
- Principal investigator, David Diaz-Sanchez, Environmental Protection Agency (EPA)
- Investigators
- David Diaz-Sanchez, PhD, Principal investigator, U.S. Environmental Protection Agency
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01981135
- Sponsor's protocol ID
- #11-0772
- Acronym
- TROPICOZ
- Status last verified
- Feb 2015
- First submitted
- 22 Oct 2013
- Last updated
- 10 Feb 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interaction Effects of Temperature and Ozone
- ClinicalTrials.gov ID
- NCT01981135
- Acronym / sponsor ID
- TROPICOZ / #11-0772
- Keywords
- Controlled Human exposure study, Air Pollution, Temperature, Lung Function, Cardiovascular
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 16 participants (actual)
- Lead sponsor
- Environmental Protection Agency (EPA)US federal agency
- Study start
- Sep 2011
- Primary completion
- Mar 2014 (actual)
- Study completion
- Jan 2015 (actual)
- First posted
- 11 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose: The purpose of this protocol is to understand how individuals respond to the air pollutant ozone at elevated temperatures. Ultimately, this will help us understand what the risks from poor air quality are during a heat wave.
Participants: We will recruit up to 30 healthy adults, 18-55 years old, to participate in this study.
Procedures (methods): Subjects will be exposed to clean air and to 0.3 ppm of ozone for 2 hours with intermittent exercise in a controlled environment chamber. For each exposure the temperature in the chamber will be between 31-34oC (88-93 oF). Because the aim of the study is to mimic high exposure during a heat wave, we will perform exposures only on days when mean ambient temperatures was less than 24 oC in Chapel Hill on the previous day.
Primary endpoints will include spirometry and Heart Rate Variability monitoring. Secondary endpoints will include analysis of blood clotting/coagulation factors, and analysis of soluble factors present in plasma.
Detailed description
Over the past decades, air quality in the U.S. has improved significantly. Even so, millions of people in the U.S. still live in counties that do not meet air quality standards for one or more pollutants. Global climate change is widely accepted to be occurring and is thought to have a range of major and potentially adverse effects on the ecosystem. Additionally, changes in the climate can lead to higher concentrations of harmful air pollutants, and the presence of some air pollutants in the atmosphere can also accelerate climate change. Health effects are impacted by complex interactions between climate change and air quality. Research is needed to identify the public health consequences of these interactions. One aspect that has been understudied is how physiological responses to elevated temperature are impacted by the additional stressor of air pollution.
Several epidemiological studies have shown a strong link between exposure to air pollution and adverse cardiopulmonary effects, such as respiratory tract infections, exacerbation of asthma, chronic bronchitis, ischemic heart disease, and stroke [1-3]. Ozone is a major component of photochemical smog. Controlled human exposure studies have been critical in demonstrating that it can cause decrements in lung function [4-10] and lung inflammation.[11-13] The inflammation includes increased neutrophils and soluble pro-inflammatory mediators in the lower airways [14, 15].
The majority of these studies involved controlled exposures to relatively high (0.1 - 0.4ppm) concentrations for short periods of time (typically 2 hours). These short-term exposure studies are useful because a) they provide the strongest and most quantifiable exposure-response data and b) they allow the investigation of biological changes that in themselves are transient and inconsequential but can be extrapolated to predict health outcomes in susceptible populations or in long-term exposures. For example, healthy individuals exposed to 0.4ppm ozone exposure for 2hr [16] showed a13.5 % decrement in FEV1, often accompanied by only mild symptoms such as tracheobronchial irritation and cough. However, by 3hours after exposure, these symptoms had largely disappeared and only a 2.7% FEV1 decrement was detectable. By 24hrs, even at higher ozone concentrations the recovery phase has normally completed. The primary public health concern is in individuals with respiratory disease. If these same changes occurred in a person with reduced reserve, the ozone-induced changes would be superimposed on preexisting pulmonary impairment and may have significant health effects.
Despite almost 30 years of research into the effects of ozone, there are very few studies of the interaction between ozone and temperature. Although ozone is normally elevated when the weather is dry and hot, most controlled chamber studies are performed at moderate temperatures (70-75 oF). Those studies that addressed higher temperatures were generally performed in the run-up to the Los Angeles Olympics in 1984 and centered on impairment of exercise performance. For example, Gibbons and Adams studied ten aerobically trained young adult females exercised continuously at 66% of maximum O2 uptake for 1 h while exposed orally to filtered air and 0.15 and 0.30 ppm ozone in both moderate (24 degrees oC) and hot (35 degrees oC) ambient conditions and showed that subjects were more likely to cease exercising prematurely at hot temperatures.[17] Gong studied elite cyclists and showed similar results.[18] Folinsbee et al., studied the effects of a 2-h exposure to high level ozone (0.5 ppm) in 14 nonsmoking males under four environmental conditions (64.4, 80.0, 85.2, and 92.0 oF) and found that the greatest decrease in FVC occurred when ozone exposures were at the highest temperature.[19]
Those cited studies have focused on respiratory outcomes. Yet it is becoming clear that ozone may have systemic and cardiac effects. Ozone reacts rapidly with respiratory tissues and is not absorbed or transported to extrapulmonary sites. However, recent studies have also shown associations between long-term ozone exposure and cardiovascular morbidity [20, 21]. In addition, short-term exposures to ozone may cause minor transient changes in high frequency heart rate variability (HRV) in healthy adults [22]. Experimental studies have shown that heat stress can have a similar modest effect on this component of HRV. [23] The effect of the combination has not been studied to date. Epidemiology studies assessing the ozone-temperature-cardiac relationship have generally been uninformative since high ozone days normally occur during hot weather. Traditional methods are not suitable to discriminate between the effects of ozone and temperature, let alone their interaction. Those that have studied the relationship have shown a negative association between temperature and ozone-mortality due to increased use in air conditioning. [24] A very recent study, however, using novel approaches examined whether ozone modified the associations between temperature and cardiovascular mortality in 95 large communities in the USA, 1987-2000, in summer. They found that a 10oC increase in temperature on the same day was associated with an increase in mortality by 1.17% and 8.31% for the lowest and highest level of ozone concentrations in all communities, respectively.[25]
The purpose of this study is to perform the first controlled chamber study in order to understand the cardiovascular changes resulting from the interaction between heat and ozone. The information obtained from this study will enable the EPA to evaluate better the risks from air pollutants during a heat wave and provide advice on activities to mitigate the effects.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Clean Air | Sham comparator | Other: Clean AirExposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. |
| Ozone | Experimental | Other: OzoneExposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- 1. Pass a physical exam performed by study physicians during the screening visit under a separate protocol.
Key exclusion criteria (5 listed)
- 1. A history of chronic illnesses such as diabetes, rheumatological diseases, immunodeficiency state, known clinically significant cardiac disease (including myocardial infarction, congestive heart failure and angina), chronic respiratory diseases such as chronic obstructive pulmonary disease, asthma and lung cancer.
- 2. If the subject is pregnant, attempting to become pregnant or breastfeeding. 3. Subjects currently taking medications which may impact the results of the ozone challenge or interfere with any other medications potentially used in the study (to include systemic steroids and beta blockers). Subjects must refrain from all over the counter anti-inflammatory agents, and anti-oxidants for a period of one week prior to exposure. Medications not specifically mentioned here may be reviewed by the investigators prior to a subject's inclusion in the study.
- 4. Smoking history within 2 years of the study. 5. Untreated hypertension (≥ 150 systolic, ≥ 90 diastolic). 6. Skin diseases or sensitivity precluding the use of ECG electrodes. 7. Symptom score greater than 21 (out of a possible 40-see accompanying score sheet) for total symptom score. Only one score may be equal to 3.
- 8. Dementia. 9. Unspecified illness or condition which in the judgment of the investigator might increase the risk associated with inhalation challenge or exercise.
- 10. Subjects who do not understand or speak English. 11. Subjects who are unable to perform moderate exercise.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clean AirEach subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period. | Other | Clean Air |
| OzoneAlso: O3Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period. | Other | Ozone |
Primary outcome
Forced expired volume in the first second (FEV1)
Time frame: Pre exposure to 24hours post exposure
Forced expired volume in the first second (FEV1) is determined by spirometry performed on a dry seal spirometer interfaced to a computer.
4 secondary outcomes
Index of clotting/coagulation factor
Time frame: Pre exposure to 24hours post exposure
Index of inflammatory markers
Time frame: Pre exposure to 24hours post exposure
Forced Vital Capacity
Time frame: Pre exposure to 24hours post exposure
Changes in heart rate variability
Time frame: Pre exposure to 24hours post exposure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2015.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Diaz-Sanchez, PhD principal investigator
U.S. Environmental Protection Agency
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clean Air and Ozone in people with Exposure to Environmental Pollution, Non-occupational, run by Environmental Protection Agency (EPA) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forced expired volume in the first second (FEV1) (time frame: Pre exposure to 24hours post exposure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2015.